Pharmacuetical Composition and Method of Treating Hematologic Malignancies

A method of suppressing leukemia, lymphoma, and myeloma malignancies in a patient in need thereof including administering a pharmaceutical composition including a therapeutically effective amount of 64Zne to said patient, wherein from about 0.4 μg/kg of patient weight to about 1.682 g/kg of patient weight of 64Zne is administered to said patient, wherein the 64Zne is at least 90% 64Zn , and wherein the 64Zne is in elemental, atomic, ionic, or nascent form.

A method of suppressing leukemia, lymphoma, and myeloma malignancies in a patient in need thereof including administering a pharmaceutical composition including a therapeutically effective amount of 64Zne to said patient, wherein from about 0.4 μg/kg of patient weight to about 1.682 g/kg of patient weight of 64Zne is administered to said patient, wherein the 64Zne is at least 90% 64Zn , and wherein the 64Zne is in colloidal form.

4-7. (canceled)

A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn , and wherein (Asp) is replaced by indole-3-carbinol or isoleucine enriched for the L-enantiomer to at least 90% and the resulting molecule size is below 700 Da.

A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn , and wherein aspartate is replaced by one or more of quercetin, apigenin, genistein, kaempferol, and chrysin, wherein the resulting molecule size is below 700 Da.

A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of and wherein aspartate is replaced by one or more of 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn , and wherein aspartate is replaced by one or more of curcumin, epigallocatechin gallate, or resveratrol, wherein the resulting molecule size is below 700 Da.

(canceled)

A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn , and wherein the composition includes a carrier selected from an ionophore, metallophore, polymeric micelle, metal organic framework, liposome, or a loaded platelet.

(canceled)